Trop2-targeted PET/CT imaging with 68 Ga-MY6349 improves diagnostic accuracy and influences clinical management in breast cancer.
Trop2-targeted PET/CT changed cancer stage in 20% of newly staged patients
Trop2-targeted PET/CT imaging with 68 Ga-MY6349 improves diagnostic accuracy and influences clinical management in breast cancer.
Trophoblast cell-surface antigen 2 (Trop2) is an essential therapeutic target in breast cancer, yet non-invasive methods for assessing its expression and predicting response to Trop2-directed antibody-drug conjugates (antibody-drug conjugates) remain limited.
We aimed to evaluate the diagnostic accuracy of 68 Ga-MY6349 positron emission tomography/computed tomography (PET/CT) in patients with breast cancer and assess its impact on clinical decision-making.
We prospectively enrolled 73 patients with suspected or confirmed breast cancer who underwent both 68 Ga-MY6349 and 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT from December 2024 to April 2025.
In the restaging cohort (n = 43), clinical management was altered in 5/43 patients (12%) owing to the identification of additional metastatic lesions or rectification of false-positive findings via 68 Ga-MY6349 PET/CT.
Exploratory analysis in three patients receiving Trop2-antibody-drug conjugates therapy showed that early changes in 68 Ga-MY6349 uptake after two treatment cycles were concordant with the subsequent clinical response.
68 Ga-MY6349 PET/CT demonstrated superior diagnostic performance to 18 F-FDG PET/CT in breast cancer staging and diagnosis, directly influencing therapeutic strategies.
Preliminary findings from the triple-negative breast cancer cases suggest that early changes in SUV max may be associated with the treatment response to Trop2-targeted antibody-drug conjugates therapy, warranting further prospective validation in larger patient populations.